[The management in chronic kidney disease (CKD)].
Renal fibrosis is the principal process underlying the progression of chronic kidney disease (CKD) to end stage renal disease (ESRD). It is a relatively uniform response involving glomerulosclerosis, tubulointerstitial fibrosis and changes in renal vasculature. Direct or indirect tubulointerstitial injury via oxidative stress and various effector molecules trigger cellular responses like tubular epithelial cell (TEC) apoptosis, activation of fibroblasts and their phenotypic switch to myofibroblasts, proliferation of macrophages, fibrocytes, fibroblasts as well as epithelial to mesenchimal transition of TEC. In this review we explore the potential of experimental therapeutic strategies, based on preventing or reversing the pathophysiologic steps of kidney remodeling that lead to fibrosis.
Busuioc
Mihaela
M
Facultatea de Medicină, Universitatea de Medicină si Farmacie Gr.T. Popa Iaşi.
Gusbeth-Tatomir
P
P
Covic
A
A
D017209:Apoptosis / Q000187:drug effects; D002908:Chronic Disease; D018450:Disease Progression; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D018384:Oxidative Stress / Q000187:drug effects; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*